McKeithan Pain Treatment Center

Home

Canadian Corporate News - IntelGenx Proprietary Delivery Technology Tested in Cannasat Therapeutics' Phase I Study for Drug Treatment for Neuropathic Pain. Published on: Mon, 10 Sep 2007 07:00:00 GMT September 10, 2007 -- SAINT LAURENT, QUEBEC, Sep 10, 2007 (CCNMatthews via COMTEX) -- IntelGenx Technologies Corp. (OTCBB:IGXT.OB) ("IntelGenx"), a drug... More »		Latest Newsbits 30,000 Children with Form Of Juvenile Rheumatoid Arthritis May Have New Treatment Option (Newswise) Early and Aggressive Combination Treatment May Result in Prolonged Remission of Rheumatoid Arthritis (Newswise) Ask a vet: Treatment options will ease dog's pain (Knoxville News Sentinel) Back Pain (Westerly Sun) Many doctors give patients placebo treatment (Reuters via Yahoo! News) View all news bits Newest Articles PR Newswire Europe - Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment. Canadian Corporate News - Labopharm and Paladin Complete Canadian Licensing and Distribution Agreement for Labopharm's Once-Daily Tramadol Product; Product Expected to Fulfill Need Not... American Family Physician - Operative vs. nonoperative treatment for back pain Women's Health Advisor - Coping with carpal tunnel syndrome: this common condition can be very painful, but effective treatments can reduce your suffering Health News - Advances in diagnostic radiology and RFA aid cancer detection and treatment: recent innovations enable earlier treatment with shorter hospital stays and less... View all articles Latest Media Aquatic Arthritis Exercises for Arthritis Pain Treatment : Shoulder Wave: Aquatic Exercise for Arthritis Aquatic Arthritis Exercises for Arthritis Pain Treatment : Arm Sweeps: Aquatic Arthritis Exercise Aquatic Arthritis Exercises for Arthritis Pain Treatment : Aquatic Side Arm Circles Arthritis Exercise physical therapy for headache with neck pain Interventional Pain Management View all media

McKeithan Pain Treatment Center

Canadian Corporate News - IntelGenx Proprietary Delivery Technology Tested in Cannasat Therapeutics' Phase I Study for Drug Treatment for Neuropathic Pain.